Boston Partners lowered its stake in UnitedHealth Group Inc (NYSE:UNH) by 8.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,366,027 shares of the healthcare conglomerate’s stock after selling 232,230 shares during the quarter. Boston Partners owned about 0.24% of UnitedHealth Group worth $521,614,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. Beach Investment Management LLC. purchased a new stake in shares of UnitedHealth Group during the 2nd quarter valued at about $556,000. WESPAC Advisors LLC purchased a new stake in shares of UnitedHealth Group during the 2nd quarter valued at about $206,000. Schroder Investment Management Group raised its position in shares of UnitedHealth Group by 0.7% during the 2nd quarter. Schroder Investment Management Group now owns 2,138,109 shares of the healthcare conglomerate’s stock valued at $396,127,000 after buying an additional 13,915 shares in the last quarter. WealthTrust Fairport LLC purchased a new stake in shares of UnitedHealth Group during the 2nd quarter valued at about $201,000. Finally, Tredje AP fonden raised its position in shares of UnitedHealth Group by 15.1% during the 2nd quarter. Tredje AP fonden now owns 144,989 shares of the healthcare conglomerate’s stock valued at $26,884,000 after buying an additional 19,030 shares in the last quarter. Institutional investors and hedge funds own 86.83% of the company’s stock.
UnitedHealth Group Inc (UNH) opened at $222.77 on Tuesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.73 and a quick ratio of 0.73. The company has a market cap of $215,570.00, a PE ratio of 23.45, a price-to-earnings-growth ratio of 1.31 and a beta of 0.74. UnitedHealth Group Inc has a one year low of $162.74 and a one year high of $250.79.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 20th. Shareholders of record on Friday, March 9th will be paid a $0.75 dividend. The ex-dividend date of this dividend is Thursday, March 8th. This represents a $3.00 dividend on an annualized basis and a yield of 1.35%. UnitedHealth Group’s dividend payout ratio is currently 31.58%.
In other UnitedHealth Group news, CEO Larry C. Renfro sold 22,598 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $221.75, for a total value of $5,011,106.50. Following the transaction, the chief executive officer now directly owns 195,314 shares in the company, valued at approximately $43,310,879.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William C. Ballard, Jr. sold 10,000 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The stock was sold at an average price of $246.38, for a total transaction of $2,463,800.00. Following the completion of the transaction, the director now owns 76,637 shares in the company, valued at $18,881,824.06. The disclosure for this sale can be found here. Insiders sold a total of 53,196 shares of company stock worth $12,291,179 over the last 90 days. Insiders own 0.89% of the company’s stock.
Several analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of UnitedHealth Group from a “hold” rating to a “buy” rating and set a $267.00 target price on the stock in a research report on Saturday, January 20th. Argus upped their price target on shares of UnitedHealth Group to $270.00 and gave the company a “buy” rating in a report on Thursday, January 18th. Deutsche Bank upped their price target on shares of UnitedHealth Group to $260.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Citigroup upped their price target on shares of UnitedHealth Group from $235.00 to $268.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $259.00 price target on shares of UnitedHealth Group in a report on Wednesday, January 17th. Two analysts have rated the stock with a hold rating and twenty-six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $245.14.
COPYRIGHT VIOLATION WARNING: “UnitedHealth Group Inc (UNH) Shares Sold by Boston Partners” was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/03/13/unitedhealth-group-inc-unh-shares-sold-by-boston-partners.html.
UnitedHealth Group Company Profile
UnitedHealth Group Incorporated is a health and well-being company. The Company operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight and OptumRx. It conducts its operations through two business platforms: health benefits operating under UnitedHealthcare and health services operating under Optum.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.